➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: May 25, 2020

DrugPatentWatch Database Preview


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for APIDRA SOLOSTAR

Identify potential brand extensions & biosimilar entrants

SanofiPhase 4

See all APIDRA SOLOSTAR clinical trials

Recent Litigation for APIDRA SOLOSTAR

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.2016-11-30
Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp.2016-09-16

See all APIDRA SOLOSTAR litigation

PTAB Litigation
Pfizer Inc.2019-05-02
Mylan Pharmaceuticals Inc.2018-10-29

See all APIDRA SOLOSTAR litigation

Company Disclosures: US Patents for APIDRA SOLOSTAR

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629 003 2005-12-20   Start Trial Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) 2017-06-20 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for APIDRA SOLOSTAR

These patents were identified by searching patent claims

Supplementary Protection Certificates for APIDRA SOLOSTAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132005901285503 Italy   Start Trial PRODUCT NAME: INSULINA GLULISINE(APIDRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/04/285/001-020, 20040927
2/2005 Austria   Start Trial PRODUCT NAME: INSULIN GLULISINE; REGISTRATION NO/DATE: EU/1/04/285/001-020 20040927
SPC/GB05/024 United Kingdom   Start Trial PRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTERED: UK EU/1/04/285/001 20040929; UK EU/1/04/285/002 20040929; UK EU/1/04/285/003 20040929; UK EU/1/04/285/004 20040929; UK EU/1/04/285/005 20040929; UK EU/1/04/285/006 20040929; UK EU/1/04/285/007 20040929; UK EU/1/04/285/008 20040929; UK EU/1/04/285/009 20040929; UK EU/1/04/285/010 20040929; UK EU/1/04/285/011 20040929; UK EU/1/04/285/012 20040929; UK EU/1/04/285/013 20040929; UK EU/1/04/285/014 20040929; UK EU/1/04/285/015 20040929; UK EU/1/04/285/016 20040929; UK EU/1/04/285/017 20040929; UK EU/1/04/285/018 20040929; UK EU/1/04/285/019 20040929; UK EU/1/04/285/020 20040929
122004000049 Germany   Start Trial PRODUCT NAME: INSULIN GLULISINE; REGISTRATION NO/DATE: EU/1/04/285/001-020 20040927
251 Finland   Start Trial
91138 Luxembourg   Start Trial 91138, EXPIRES: 20190927
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.